MaaT Pharma
ISIN: FR0012634822 | Ticker: MAAT | LEI: 969500CQQB6XUNW6CN97
Country: France
Building a leading microbiome company in oncology
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome.
2014
Served areaWorldwide
Headcount50
Headquarters70 Avenue Tony Garnier, 69007 Lyon – France
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 22.12.23 | None | Other | Buy | EUR 14,994.00 |
| 22.12.23 | None | Other | Buy | EUR 9,996.00 |
| 27.09.23 | None | Other | Buy | EUR 3,050.00 |
FR0012634822
LEI969500CQQB6XUNW6CN97
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.